Fujian Cancer Hospital

• NCT07691333

  Phase 2, Not yet recruiting, 35 people, 8 Jul 2026

• NCT07613567

  Phase 3, Not yet recruiting, 486 people, 29 May 2026

• NCT07581834

  Phase 2, Recruiting, 2,000 people, 12 May 2026

• Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

  Phase 2, Recruiting, 130 people, 13 Mar 2026

• NCT07185308

  Collaborator, Not yet recruiting, 150 people, 22 Sept 2025

• NCT07155122

  Phase 2, Not yet recruiting, 15 people, 4 Sept 2025

• NCT07154316

  Collaborator, Phase 2, Recruiting, 138 people, 4 Sept 2025

• NCT07101159

  Phase 2, Not yet recruiting, 200 people, 3 Aug 2025

• NCT07046221

  Phase 2, Not yet recruiting, 60 people, 1 Jul 2025

• NCT07001540

  Collaborator, Phase 2, Recruiting, 130 people, 3 Jun 2025

• NCT06793917

  Phase 3, Recruiting, 269 people, 27 Jan 2025

• PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

  Phase 2, Recruiting, 35 people, 23 Jan 2025

• NCT06787183

  Phase 2, Recruiting, 42 people, 22 Jan 2025

• NCT06786312

  Phase 2, Not yet recruiting, 34 people, 22 Jan 2025

• NCT06614621

  Phase 2, Not yet recruiting, 43 people, 26 Sept 2024

• NCT06496308

  Collaborator, Phase 3, Recruiting, 78 people, 11 Jul 2024

• NCT06490913

  Phase 2, Status unknown, 33 people, 8 Jul 2024

• NCT06417476

  Collaborator, Phase 2, Active, not recruiting, 66 people, 16 May 2024

• NCT06396585

  Phase 2, Status unknown, 28 people, 2 May 2024

• NCT06333769

  Phase 2, Completed, 38 people, 27 Mar 2024

Sources: clinicaltrials.gov